Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
10.1038/s41598-019-52082-z 58
10.3390/brainsci10080534 177 MukhopadhyayS.LinstedtA
Key Findings: Large human studies across multiple countries have not found increased thyroid cancer rates in GLP-1 users The FDA warning applies to medullary thyroid carcinoma (MTC)only 3-4% of all thyroid cancers The warning exists because rodents developed C-cell tumors, but humans and rodents differ biologically Some studies show associations, but these are explained by detection bias (more monitoring = finding pre-existing nodules) The Clayman Thyroid Center (2,000+ thyroid cancer patients/year) has not seen an MTC pattern linked to GLP-1 use (or for that matter any other thyroid malignancy) Clinical Recommendations: Patients with MTC history or MEN2 should not take GLP-1 receptor agonists Patients with common thyroid cancers (papillary, follicular, Hrthle cell) should not assume GLP-1 caused them or will have an effect upon them Decisions should be individualized, weighing metabolic benefits against theoretical concerns GLP-1 therapy does not require additional thyroid monitoring Quick Reference for Clinicians Understanding the Question What Medications Are We Discussing
If you weighed 100kg, this would be a weight loss of 25kg
US$ 28.53
US$ 23.67
US$ 25.54
US$ 22.03
